sj-pdf-3-mso-10.1177_2055217321990852 - Supplemental material for Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study

Supplemental material, sj-pdf-3-mso-10.1177_2055217321990852 for Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study by Mark S Freedman Department of Medicine and the Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada, Patricia K Coyle Department of Neurology, Stony Brook University, Stony Brook, NY, USA, Giancarlo Comi Institute of Experimental Neurology, IRCCS Ospedale San Raffaele, Milan, Italy, Susan L Scarberry Sanford Health Multiple Sclerosis Center, Fargo, ND, USA, Doris Damian EMD Serono Research & Development Institute, Inc, Billerica, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany, Yann Hyvert Merck KGaA, Darmstadt, Germany, Fernando Dangond EMD Serono Research & Development Institute, Inc, Billerica, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany,Andrew Galazka, Dominic JackMerck KGaA, Darmstadt, Germany, Lori A Lebson EMD Serono, Inc, Rockland, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany, Thomas P Leist Comprehensive Multiple Sclerosis Center, Jefferson University Hospital, Philadelphia, PA, USA in Multiple Sclerosis Journal – Experimental, Translational and Clinical